Skip to main content

Advertisement

SpringerLink
Log in

A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy

  • Case Reports
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease. Trastuzumab, as a second line treatment, has shown a 15% objective response rate in patients with metastatic breast cancer.

We present the case of a patient with two breast tumours, the second of more aggressive characteristics, with negative hormone receptors and c-erb-B2 +++, and with few therapeutic options due to her hepatic insufficiency secondary to metastatic disease; she was administered herceptin as monotherapy, and she had a complete clinical response. Trastuzumab has revolutionised the management of patients with metastatic breast cancer and Her-2-neu overexpression. Its combination with chemotherapy agents achieves a synergic activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neuoverexpressing metastatic breast cancer. Am J Ther. 2005;12(3):243–53.

    PubMed  Google Scholar 

  2. De Laurentiis M, Cancello G, Zinno L, et al. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Ann Oncol. 2005;16 Suppl 4:S7–13.

    Google Scholar 

  3. Luftner D, Pollmann D, Schildhauer S, et al. Perspectives of immunotherapy in metastatic breast cancer. Anticancer Res. 2005;25(6C):4599–604.

    PubMed  CAS  Google Scholar 

  4. Rossi A, Colantuoni G, Cantore N, et al. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case. Anticancer Res. 2004;24(1):317–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Elche University General Hospital. Eche, C/ Cami de l'Almazara, 11 03203 Elche, Alicante, Spain

    Sonia Maciá Escalante, Álvaro Rodríguez Lescure, Vanesa Pons Sanz, Natividad Martínez Banaclocha, Carmen Guillén Ponce & Alfredo Carrato Mena

Authors
  1. Sonia Maciá Escalante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Álvaro Rodríguez Lescure
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vanesa Pons Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natividad Martínez Banaclocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carmen Guillén Ponce
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alfredo Carrato Mena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonia Maciá Escalante.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Escalante, S.M., Lescure, Á.R., Sanz, V.P. et al. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol 8, 761–763 (2006). https://doi.org/10.1007/s12094-006-0125-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-006-0125-6

Key words

Search

Navigation